Repare Therapeutics to introduce primary data from its clinical trial

Image Credit: Stock Events

Announcement 

Repare Therapeutics Inc., a leading clinical-level precision oncology company, has presented primary data on excellent tolerability, early efficacy, and safety from its previous Phase 1 LIONS trial as a poster presentation at the 37th AACR-NCI-EORTC International Conference on Cancer Therapeutics and Molecular Targets. The conference will be held in Boston, MA, on October 22-26, 2025. The company has already achieved excellence in developing the targeted cancer therapies aiming at the genomic instability, involving DNA damage repair. The data will surely be effective and impressive for further drug development. The data will be a proven attempt to harness the next-generation treatment for the tumour or other conditions, supporting treatment and advancement growth. The data will pave the way for advancement and improvement in the healthcare sector.

The LIONS clinical trial (NCT06232408) is a centre, open-label, first-in-human Phase 1 study to examine the pharmacodynamics, preliminary efficacy, safety, and pharmacokinetics of RP-1664. The RP-1664 is a superior selective, best first-in-class, oral PLK4 inhibitor discovered for adolescent and adult patients monotherapy treatment with TRIM37-high solid tumours.

Presentation in detail

The title of the presentation is ‘Preliminary safety and antitumor activity of RP-1664, a first-in-class PLK4 inhibitor, as monotherapy in advanced solid tumours with and without TRIM37 amplification’. The presenter of the presentation will be Columbia University, MD, Benjamin Herzberg (abstract no. LB-C002). The presentation will be held under session C, at level 2, exhibit hall D on Saturday, 25^th October, between 12:30 pm – 4:00 pm. The copy of the poster presentation can be fetched on the scientific resources page of the repare therapeutics website at the time of the poster presentation session.

Short detail of RP-1664

The RP-1664 is engineered to support the synthetic lethal connection with TRIM37 overexpression or amplification in solid tumours. Tumours depend on PLK4 for effective centriole biogenesis in the S timeline of the cell cycle. In the situation when TRIM37, an E3 ligase that mitigates pericentriolar material when high. The preclinical studies elaborate that the RP-1664 drives potent synthetic lethality and selectively inhibits PLK4 in TRIM37-high tumour models in vivo and vitro. The TRIM37 has been accelerated due to its excellent features spotted throughout the wide range of solid tumours and is estimated to be 80% of all super-grade neuroblastomas. The RP-1664 is the one and only first selective PLK4 inhibitor said to be in the clinic.